Regadenoson
Regadenoson is an adenosine A2A receptor agonist that displays vasodilatory activity. Regadenoson is clinically used in myocardial perfusion imaging.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18957970
| Cas No. |
313348-27-5 |
|---|---|
| Purity |
≥98% |
| Formula |
C15H18N8O5 |
| Formula Wt. |
390.35 |
| IUPAC Name |
1-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]-N-methylpyrazole-4-carboxamide |
| Appearance |
White to off white powder |
Palani G, Ananthasubramaniam K. Regadenoson: review of its established role in myocardial perfusion imaging and emerging applications. Cardiol Rev. 2013 Jan-Feb;21(1):42-8. PMID: 22643345.
Cerqueira MD. The future of pharmacologic stress: selective A2A adenosine receptor agonists. Am J Cardiol. 2004 Jul 22;94(2A):33D-40D; discussion 40D-42D. PMID: 15261132.
